Addex ceo steps down

Replacement being sought for Swiss allosteric modulators developer

Vincent Mutel has stepped down from his position as chief executive of Addex Pharmaceuticals, a Swiss developer of allosteric modulators for human health based in Geneva.

André Mueller, chairman of Addex, will act as executive chairman and lead an operational subcommittee of directors to manage the transition until a new ceo is appointed.

Under Mutel's leadership, Addex says it has become a world leader in the field of allosteric modulator drug discovery and has formed significant drug development partnerships with leading pharmaceutical companies.

The board of directors has invited Mutel to consider a possible future advisory role at Addex.

You may also like

Research & Development

Addex moves R&D operations to Campus Biotech in Geneva

To advance its portfolio of allosteric modulator drug candidates
Research & Development

Addex cuts staff from 19 to 2 people

CEO Bharatt Chowira and executive management step down
Research & Development

Addex to cut 28 jobs at Geneva operation

This is a strategic move from a position of strength, says ceo
You need to be a subscriber to read this article.
Click here to find out more.
Research & Development

Masters of synthesis

Medicinal chemists take an initial lead compound and through systematic design work improve its potency, efficacy, and properties such as solubility and metabolism. The aim is to create a molecule that is effective, has few side-effects and can be scaled up, initially for clinical trials and subsequently for commercial manufacturing.
Research & Development

Addex makes job cuts to reduce costs

Restructures to focus on core r&d programmes and strategic partnerships
Research & Development

From lab to launch: transforming pharmaceutical formulation development with GEA’s CFC Lab Coater

A new generation of continuous film coating technology is giving R&D teams the speed, precision and scalability they need to take products from the laboratory to commercial production without the traditional bottlenecks
Manufacturing

Bristol Myers Squibb licenses Lonza ADC linker-payload technology for undisclosed target

BMS has secured exclusive access to Lonza’s SYNtecan linker-payload platform, alongside GlycoConnect and HydraSpace technologies, to advance development of an antibody-drug conjugate against an undisclosed target
Subscribe now